Allergan Names Douglas S. Ingram President


Douglas S. Ingram.
IRVINE, Calif.— Allergan, Inc. (NYSE:AGN) has named Douglas S. Ingram as president. In this newly established role, Ingram will report directly to David E.I. Pyott, chairman of the board and CEO. He will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer and medical device products including leading ophthalmology products such as Restasis, Lumigan, Alphagan, Combigan, Ganfort, Optive and Ozurdex.

With more than 25 years of professional experience, Ingram has a strong background in the health care industry, both in the U.S. and internationally. He has served Allergan as executive vice president and president, Europe, Africa and the Middle East for the past three years. In this role, he was responsible for Allergan's regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development and general management.

Prior to that, Ingram served as executive vice president and chief administrative officer. In this role, at various times, he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. He also served as Allergan's secretary and chief ethics officer from July 2001 to July 2010. Ingram joined Allergan in 1996 as senior attorney and chief litigation officer and was promoted to associate general counsel and assistant secretary, and later, to general counsel.

“During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business,” said Pyott. “Doug has built an impressive record of accomplishment and is widely regarded throughout our organization as a leader who is committed to the highest standards of excellence in all areas. I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role.”